Effect of protoconized therapy for renal anemia on adverse events of patients with maintenance hemodialysis

被引:2
作者
Kuragano, Takahiro [1 ]
Yahiro, Mana [1 ]
Kida, Aritoshi [1 ]
Furuta, Minoru [1 ]
Nagasawa, Yasuyuki [1 ]
Hasuike, Yukiko [1 ]
Nanami, Masayoshi [1 ]
Nakanishi, Takeshi [1 ]
机构
[1] Hyogo Coll Med, Dept Internal Med, Div Kidney & Dialysis, Nishinomiya, Hyogo, Japan
基金
日本学术振兴会;
关键词
Anemia; Hemodialysis; Erythropoiesis-stimulating agent; Iron; Vitamin C; CHRONIC KIDNEY-DISEASE; ERYTHROPOIESIS-STIMULATING AGENTS; INTRAVENOUS ASCORBIC-ACID; EPOETIN-ALPHA; ELEVATED FERRITIN; HEMOGLOBIN LEVEL; SERUM FERRITIN; ORAL IRON; HEPCIDIN; HYPERFERRITINEMIA;
D O I
10.5301/ijao.5000370
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Purpose: We evaluate the effect of the protoconized anemia therapy on adverse events using the Hb and ferritin levels of individual patients undergoing maintenance hemodialysis (MHD). Methods: Design: A randomized, parallel group, multi-center study. Patients: Two hundred sixty-six MHD patients. Intervention group: The doses of erythropoietin, iron, and vitamin C were adjusted every month based on the ferritin and hemoglobin (Hb) levels according to the protocol. Non-intervention group: The attending physician determined the doses of erythropoietin and iron. Results: The maintenance rate of target Hb and ferritin levels were significantly higher in the Intervention group than in the Non-intervention group. The frequency of hospitalization was significantly lower for patients with a higher maintenance rate of target Hb levels than for those with a lower maintenance rate. Conclusions: Using an anemia treatment protocol according to the individual Hb and ferritin levels of hemodialysis patients might stabilize the Hb and ferritin levels, which in turn could contribute to the lower frequency of adverse events in MHD patients.
引用
收藏
页码:865 / 874
页数:10
相关论文
共 29 条
  • [1] Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia
    Attallah, N
    Osman-Malik, Y
    Frinak, S
    Besarab, A
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2006, 47 (04) : 644 - 654
  • [2] The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin
    Besarab, A
    Bolton, WK
    Browne, JK
    Egrie, JC
    Nissenson, AR
    Okamoto, DM
    Schwab, SJ
    Goodkin, DA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) : 584 - 590
  • [3] Exploring relative mortality and epoetin alfa dose among Hemodialysis patients
    Bradbury, Brian D.
    Wang, Ouhong
    Critchlow, Cathy W.
    Rothman, Kenneth J.
    Heagerty, Patrick
    Keen, Marcia
    Acquavella, John F.
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2008, 51 (01) : 62 - 70
  • [4] BRIDGES KR, 1986, J BIOL CHEM, V261, P14273
  • [5] Efficacy and safety of epoetin alfa in critically ill patients
    Corwin, Howard L.
    Gettinger, Andrew
    Fabian, Timothy C.
    May, Addison
    Pearl, Ronald G.
    Heard, Stephen
    An, Robert
    Bowers, Peter J.
    Burton, Paul
    Klausner, Mark A.
    Corwin, Michael J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (10) : 965 - 976
  • [6] Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the dialysis patients' response to IV iron with elevated ferritin (DRIVE) study
    Coyne, Daniel W.
    Kapoian, Toros
    Suki, Wadi
    Singh, Ajay K.
    Moran, John E.
    Dahl, Naomi V.
    Rizkalal, Adel R.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 18 (03): : 975 - 984
  • [7] Normalization of hemoglobin level in patients with chronic kidney disease and anemia
    Drueke, Tilman B.
    Locatelli, Francesco
    Clyne, Naomi
    Eckardt, Kai-Uwe
    Macdougall, Iain C.
    Tsakiris, Dimitrios
    Burger, Hans-Ulrich
    Scherhag, Armin
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (20) : 2071 - 2084
  • [8] Hemoglobin level variability: Associations with comorbidity, intercurrent events, and hospitalizations
    Ebben, James P.
    Gilbertson, David T.
    Foley, Robert N.
    Collins, Allan J.
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 1 (06): : 1205 - 1210
  • [9] Predictors of Hyporesponsiveness to Erythropoiesis-Stimulating Agents in Hemodialysis Patients
    Kalantar-Zadeh, Kamyar
    Lee, Grace H.
    Miller, Jessica E.
    Streja, Elani
    Jing, Jennie
    Robertson, John A.
    Kovesdy, Csaba P.
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2009, 53 (05) : 823 - 834
  • [10] Ferric gluconate reduces epoetion requirements in hemodialysis patients with elevated ferritin
    Kapoian, Toros
    O'Mara, Neeta B.
    Singh, Ajay K.
    Moran, John
    Rizkala, Adel R.
    Geronemus, Robert
    Kopelman, Robert C.
    Dahl, Naomi V.
    Coyne, Daniel W.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 19 (02): : 372 - 379